Compositions and methods for enhancing wnt signaling for treating cancer
AssigneesMassachusetts Institute of Technology, The General Hospital Corporation
InventorsGeorge Eng, Omer Yilmaz, Jonathan Braverman
Life of this patent
Estimating the term…
Loading patent…
AssigneesMassachusetts Institute of Technology, The General Hospital Corporation
InventorsGeorge Eng, Omer Yilmaz, Jonathan Braverman
Estimating the term…
Methods and compositions for enhancing Wnt signaling pathway activities in a tissue of a subject have been developed for the treatment of cancer, in particular cancers with one or more mutations in the APC (adenomatous polyposis coli) gene. Preferably, the amount of the compositions for enhancing Wnt signaling does not reduce or inhibit proliferation or viability of normal healthy cells in the subject. In some embodiments, pharmaceutical compositions including an effective amount of one or more GSK-3 inhibitors are administered to reduce cancer cell proliferation or viability in a subject. A preferred GSK-3 inhibitor is LY2090314 encapsulated within, or associated with nanoparticles. Dosage forms of LY2090314 encapsulated within, or associated with nanoparticles for administration are also described.
A method for treating adenoma, or cancer with overactivated Wnt in a subject in need thereof, comprising administering to the subject an effective amount of a composition for increasing Wnt signaling activity in adenoma or cancer cells of the subject to reduce adenoma or cancer cell proliferation and/or reduce adenoma or cancer cell viability in the subject,
(canceled)
(canceled)
-14. (canceled)
-20. (canceled)
A method of increasing regeneration of colon tissue in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition for enhancing Wnt signaling pathway activity in normal cells of the subject,
-24. (canceled)
A dosage form for injection or for oral administration comprising a GSK-3 inhibitor, or a Wnt agonist, or a combination of a GSK-3 inhibitor and a Wnt agonist in an amount effective to increase Wnt signaling activity in adenoma or cancer cells of a subject and reduce adenoma or cancer cell proliferation and/or reduce adenoma or cancer cell viability in the subject.
(canceled)
-40. (canceled)
42-43. (canceled)
(canceled)
Dependencies are inferred from the claim text.